Antiplatelet therapy added to standard thromboprophylaxis to prevent thrombosis in pancreatic cancer patients - a randomized clinical trial (The PANART trial)

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-509022-22-00

Enrollment

744

Registered

2024-08-26

Start date

2025-08-21

Completion date

Unknown

Last updated

2025-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic ductal cancer

Brief summary

Efficacy: A composite of objectively verified arterial or venous thrombosis. Safety: Major bleeding.

Detailed description

Death

Interventions

DRUGPlavix 75 mg film-coated tablets

DRUGFragmin 5 000 IE injeksjonsvæske

DRUGoppløsning i ferdigfylt sprøyte

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Efficacy: A composite of objectively verified arterial or venous thrombosis. Safety: Major bleeding.	—

Secondary

Measure	Time frame
Death	—

Countries

Norway

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026